Journal
JOURNAL OF PEDIATRICS
Volume 153, Issue 6, Pages 833-838Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2008.06.011
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R01 HL069413, R01 HL069413-03] Funding Source: Medline
- NICHD NIH HHS [U10 HD031318, 5U10 HD031318] Funding Source: Medline
Ask authors/readers for more resources
Objective To investigate the safety, tolerability, and pharmacokineties of the anti-tumor necrosis factor-alpha monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). Study design We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2 g/kg) versus infliximab (5 mg/kg) in 24 children with acute KD and fever after initial treatment with IVIG. Primary outcome measures were the safety, tolerability, and pharmacokinetics of infliximab. Secondary outcome measures were duration of fever and changes in markers of inflammation. Results Study drug infusions were associated with cessation of fever within 24 hours in 11 of 12 subjects treated with infliximab and in 8 of 12 subjects retreated with IVIG. No infusion reactions or serious adverse events were attributed to either study drug. No significant differences were observed between treatment groups in the change from baseline for laboratory variables, fever, or echocardiographic assessment of coronary arteries. Conclusions Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available